Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China

doi:10.3748/wjg.v31.i47.114377

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 47

This Article

(45)

(35)

(0)

(1)

(1086)

(4)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Dec 21, 2025; 31(47): 114377
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114377

Table 2 Baseline demographics and clinical symptoms, n (%)

		0.5 g-QID	0.75 g-QID	1.0 g-TID	P value
		568	574	575
Gender	Female	338 (59.5)	367 (63.9)	318 (55.3)	0.012
	Male	230 (40.5)	207 (36.1)	257 (44.7)
Age [median (IQR)]		46.0 (35.0-54.0)	47.0 (36.0-57.0)	45.0 (33.0-55.0)	0.021
	Lost to follow-up	14 (2.5)	10 (1.7)	17 (3.0)	0.494
	Poor adherence	10 (1.8)	11 (1.9)	10 (1.7)	0.982
Symptom relief group	Asymptomatic	340 (59.9)	317 (55.2)	325 (56.5)	0.186
	No symptom relief	6 (1.1)	7 (1.2)	9 (1.6)
	Symptom relief	208 (36.6)	240 (41.8)	224 (39.0)
Efficacy	Markedly effective	171 (83.8)	204 (88.7)	203 (91.9)	0.017
	Ineffective	21 (10.3)	10 (4.3)	7 (3.2)
	Effective	12 (5.9)	16 (7.0)	11 (5.0)
Pretreatment score [median (IQR)]		2.0 (2.0-4.0)	3.0 (2.0-4.0)	3.0 (2.0-4.0)	0.170
Post treatment score [median (IQR)]		0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.169
Adverse events		31 (5.46)	30 (5.23)	43 (7.48)	0.187

P < 0.05 was considered statistically significant. Between-group differences were assessed using χ² tests for categorical variables and Kruskal-Wallis test for continuous variables (age, pretreatment score, and posttreatment score).

Full Size Table

Citation: Wu CQ, Zhou X, Li CP, He QL, Chen ZH, Ding SB, Deng L, Chen LL, Jiang K, Dong CK, Hu L, Zhu GB, Zhang CG, Zhang Y, Wu LL, Li W, Mao YH, Zhang H, Ai X, He YQ, Ma Y, He SY. Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China. World J Gastroenterol 2025; 31(47): 114377
URL: https://www.wjgnet.com/1007-9327/full/v31/i47/114377.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i47.114377

Wu CQ, Zhou X, Li CP, He QL, Chen ZH, Ding SB, Deng L, Chen LL, Jiang K, Dong CK, Hu L, Zhu GB, Zhang CG, Zhang Y, Wu LL, Li W, Mao YH, Zhang H, Ai X, He YQ, Ma Y, He SY. Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China. World J Gastroenterol 2025; 31(47): 114377 [PMID: 41479756 DOI: 10.3748/wjg.v31.i47.114377]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.